Seizure Prophylaxis in Subarachnoid Hemorrhage
Routine seizure prophylaxis is NOT recommended for all SAH patients, but should be used selectively only in those with high-risk features including ruptured MCA aneurysm, high-grade SAH (Hunt-Hess ≥3), intracerebral hemorrhage, hydrocephalus, or cortical infarction 1.
Risk-Stratified Approach
High-Risk Patients (Use Prophylaxis)
Consider antiseizure medication prophylaxis in patients with ANY of these features 1:
- Ruptured middle cerebral artery (MCA) aneurysm
- High-grade SAH (Hunt-Hess grade ≥3)
- Intracerebral hemorrhage (ICH)
- Hydrocephalus
- Cortical infarction
The 2023 AHA/ASA guidelines provide a Class 2b recommendation (may be reasonable) for prophylaxis in this high-risk subset 1.
Low-Risk Patients (No Prophylaxis)
Do NOT use prophylactic antiseizure medications in patients without the above high-risk features - this is a Class 3 (no benefit) recommendation 1. The evidence shows no benefit and potential harm from unnecessary exposure.
Medication Selection: Avoid Phenytoin
Never use phenytoin for seizure prophylaxis in SAH patients - this is a Class 3 (harm) recommendation 1. Phenytoin is associated with:
- Excess morbidity and mortality
- Poorer cognitive outcomes
- Potential metabolic competition with nimodipine
- Higher adverse effect profile
If prophylaxis is indicated, use levetiracetam instead of phenytoin 1. While the evidence comparing agents is of very low certainty 2, levetiracetam demonstrates lower risk for neurologic decline and fewer adverse effects compared to phenytoin 1.
Duration of Prophylaxis
For Patients Presenting WITH Seizures
Treat for ≤7 days only 1. The guidelines are clear:
- Treatment for ≤7 days is reasonable to reduce perioperative seizure-related complications
- Treatment beyond 7 days is NOT effective for reducing future SAH-associated seizure risk (Class 3 recommendation) 1
For Prophylaxis in High-Risk Patients
Use short-duration prophylaxis (≤3 days) rather than extended courses 3, 4. The evidence shows:
- Long-term prophylaxis (>3 days) is associated with poor clinical outcomes (OR 1.55,95% CI 1.01-2.39) 3
- No significant difference in preventing in-hospital seizures between short and long duration 3
- Extended treatment may increase adverse effects without additional benefit 2
Key Clinical Pitfalls
Common mistake: Continuing prophylaxis until hospital discharge or beyond. This practice is not supported by evidence and may worsen outcomes 3, 4. One study found good functional outcomes (mRS 0-2) were more likely with brief (3-day) versus extended levetiracetam (83% vs 61%, p=0.04) 4.
Important caveat: The overall seizure incidence in SAH is lower than historically reported - recent studies with improved EEG monitoring suggest 7.8-15.2% rather than the previously cited 26% 1. Most seizures occur early, with early postoperative seizures at 2.3% and late seizures at 5.5% 1.
Surgical Considerations
Endovascular coiling appears associated with lower late seizure incidence compared to neurosurgical clipping 1. However, this should not drive aneurysm treatment decisions, which depend on aneurysm characteristics and other factors.
Monitoring
EEG monitoring is reasonable in high-risk patients or those with depressed neurological examination to detect subclinical seizures 1.